A novel peptide-based inhibitor of the acid sensing ion channel isoform 1a (ASIC1a)

Innovation

A peptide-based inhibitor of voltage-gated sodium channel 1.7 (Na<sub>1.7)

Innovation

Regenerative medicine technologies from the University of Queensland.

Innovation

MBL inhibitors with the potential to be developed as an adjuvant to enhance existing carbapenem antibiotics on the market.

Innovation

Saliva based diagnostic test utilising a micro RNA expression panel and salivary DNA methylation panel to address the unmet need of detecting head and neck cancers at early stages

Innovation

Potent and minimally cytotoxic small molecule antibiotics for the treatment of Carbapenem-resistant infections from Gram-negative bacteria including Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii

Innovation

Potent and minimally haemolytic new antibiotics for the treatment of Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and drug-resistant Streptococcus pneumoniae (DRSP)

Innovation

In vitro receptor-based cell proliferation assay which is fast, reliable and highly specific for assessing the potency of human growth hormone

Innovation

Small, membrane enclosed vesicles that can deliver drugs to specific intracellular targets using appropriate ligands

Innovation

Potent and stable small molecule inhibitors of cell wall synthesis in mycobacteria for the treatment of multi-drug resistant Tuberculosis

Innovation

Potent small molecule inhibitors of Prostaglandin D2 synthase for the treatment of asthma and allergic rhinitis

Innovation

Potent and stable peptide modulators of the Opioid Receptor Like-1 (ORL-1) receptor for the treatment of nociceptive pain

Innovation

A thermoresponsive polymer system for the 3D expansion of stem cells

Innovation

Orally available cyclic peptide activator of the GABA B receptor for the treatment of neuropathic pain

Innovation

Ultra-stable peptide framework amenable to incorporation of specific bioactive motifs for generation of orally active and/or tissue penetrating therapeutic peptide candidates

Innovation

Endogenously derived small peptide therapeutic with brain permeability targetting Trk receptors for treatment of neurodegenerative conditions such as Alzheimer's Disease

Innovation

Novel, selective, orally active small molecule antagonists (and agonists) of the human complement 3a receptor 2 (c3a) have been developed for the potential treatment of inflammatory diseases, metabolic syndrome and autoimmune diseases

Innovation

Stable and potent peptide mimetic framework which can be modified for a range of GPCR, transcription factor and infectious disease targets

Innovation

Novel, selective, orally active small molecule antagonists (and agonists) of the human protease-activated receptor 2 (PAR2) have been developed for the potential treatment of inflammatory diseases, metabolic syndrome and cancer.

Innovation

Non-invasive and non-pharmacological therapeutic approach for the treatment of Alzheimer’s disease and other disorders of protein aggregation

Innovation

Painless, low cost & safe cutaneous delivery system

Innovation

Novel assay to stratify patient response to EGFR inhibition and screen for novel inhibitor candidates

Innovation